anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a scavenger of active oxygen or free radical having a hydroxy radical removing effect and useful for treating a disease, etc., associated with active oxygen or free radical. SOLUTION: This scavenger contains a hydantoin derivative of the formula (R1 and R2 are each H, an alkyl or a cycloalkyl; X and Y are each H, an alkyl, OH or an alkoxy, or X and Y together form an oxo group) or its salt as an active component. As an example of a compound of the formula, 5- hydroxy-1-methylhydantoin is cited. The scavenger is effective for the treatment of various kinds of diseases such as myocardial infarction, reperfusion damage, cerebral infarction, autoimmune disease, fibrosis, pulmonary disease, skin disease. arthritis, side effect of an anticancer agent, radiation hazard, bacterial shock, inflammatory disease and cataract. The scavenger has little side effect and can be easily formulated. The daily dose of the scavenger for adult is 1-1000mg, preferably 5-600mg of the active component in oral administration.  The dose in the case of parenteral administration, e.g., in the case of an injection, is sufficiently from a third to a tenth of the dose in oral administration.
PURPOSE: A patient managing method using group communication and a device thereof are provided to increase the level of closeness between managers and a patient by enabling managers to share the information of the state of the patient. CONSTITUTION: A patient terminal requests a group call with management terminals to a patient management server (502). The patient terminal, the patient management server, a first management terminal and a second management terminal perform the call connection (503). The patient management server terminates the connection of the second management terminal potentially connected (504). The patient management server confirms connection state information and transmits the connection state information to a management terminal, which is not connected, among management terminals (505). The patient terminal and management terminal progress a call (506). If the call is completed, the patient management server confirms call result information (507,508). [Reference numerals] (11) Patient terminal; (13) Patient management server; (15-1) First management server; (15-2,15-3) Second management server; (501) Input for starting a call; (502) Request to connect to the terminal included in a patient management group list; (503) Connect to the terminal included in a patient management group list; (504) Cancel potential connection; (505) Transmit information about the state of connection; (506) Proceed calling; (507) End calling; (508) Check information about a calling result; (509) Transmit information about a calling result
The present invention discloses an EGCG-magnesium complex solid dispersion and a preparation method and application thereof. The mass ratio of EGCG-magnesium to PVP-k30 in the EGCG-magnesium complex solid dispersion is 1 to 0.5-15, the preferred ratio is 1 to 1-9, and the optimum ratio is 1 to 2-8. The EGCG is dissolved in deionized water, a magnesium salt solution (the molar ratio of the EGCG to the magnesium salt is 1 to 3) is dripped while stirring, nitrogen used for protection is led in, a saturated magnesium hydroxide solution is dripped, the PH of EGCG-magnesium complex liquid is 7.0 to 8.0, and thereby, EGCG-magnesium complex sediments are obtained. The sediments are centrifugated and collected, and are washed by deionized water, and then, the sediments are centrifugated and collected, and are suspended by deionized water. A polyvinylpyrrolidone solution is dripped into the EGCG-magnesium complex liquid while stirring, nitrogen used for protection is led in, the EGCG-magnesium complex liquid is homogenized through a high-pressure homogenizing machine and is filtered, and the filtrate is sprayed and dried to obtain the EGCG-magnesium complex solid dispersion. The EGCG-magnesium complex solid dispersion overcomes various defects existing in the EGCG and has conspicuous curative effects of the therapy of various senile diseases; the present invention solves the common problems in the therapy of senile diseases that the adaptive symptom of medication is single, the curative effect is not ideal, and the toxicity is high. The present invention has the advantages of simple preparation method and broad application prospect.
PROBLEM TO BE SOLVED: To obtain a solid composition containing an apatite-coated biodegradable polymer having compatibility with bones. SOLUTION: This solid composition containing an apatite-coated biodegradable polymer can be used as an adhesive good in bone conductivity at a fractured part or the interface of an artificial bone and a bone. A composition containing the apatite-coated biodegradable polymer with a medicine is enhanced its action to the bone and has slow releasing properties and good bone conductivity. Thus, the composition can be brought to efficiently express its effects in locally affected parts for preventing and curing bone diseases (e.g. fracture, refracture, osteoporosis, osteomalacia, bone Behcet disease, tonic spondylarthritis, chronic articular rheumatism, metaplastic knee-geniculum, destruction of arthritic tissues, etc.), repairing bone tissues after surgical operations of multiple myeloma, pulmonary carcinoma, mammary cancer, etc., and regenerating periodontal tissues in periodontitis, etc., drastically shorten curing periods and prevent from occurring various coincidences accompanied by fractures in old ages.
Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
An endoscope apparatus capable of ensuring safe and compliant use includes an endoscope, a means for identification of the endoscope, a means for determining whether the endoscope is suitable for a given medical act utilizing the identification of the endoscope, and a disablement means that prevents utilization of the endoscope when determined the endoscope is not suitable for the given medical act. The identification may be on a tag fixed to the endoscope and/or container. The information is checked for a match in a cloud database to ensure the endoscope is the right device for the medical act. If not the right device, the endoscope is deactivated. If the right device, the endoscope is activated and the cloud database is updated accordingly. The cloud database can also be updated at each point in the distribution chain to allow complete traceability.
PURPOSE: Provided is a hair care composition which contains pseudo multi emulsion drops, and simultaneously performs the cleaning and the styling functions with excellent conditioning effect. CONSTITUTION: The hair care composition comprises pseudo multi emulsion drops where hair styling polymers are contained in the circular drops of organic silicon and variants thereof or synthetic polymer. The circular drop has a size of 2-100 micrometers. The organic silicon and the variants thereof are selected from the group consisting of polydimethylsiloxanes, phenyl siloxanes, alkyl methyl siloxanes, dimethicone copolyols, trimethyl amodimethicones, and a mixture thereof. The synthetic polymer is selected from the group consisting of hydrogenated polydecene, hydrogenated C6-14 olefin polymer, polydecene, pentaerythrityl adipate/carprate/caprylate/heptanoate, and mixtures thereof. The hair styling polymer is selected from the group consisting of anionic polymers such as methacryloylethyl betaine/methacrylate polymer, cationic polymers such as polyquaternium-16, and mixtures thereof.
PROBLEM TO BE SOLVED: To provide a new polynucleotide highly identical to a nucleic acid which codes a polypeptide having a specific amino acid sequence and to be used for producing, e.g. 7TM receptor capable of binding to G-protein, and useful for treatment of infectious diseases, cancers, myocardinal infarction or the like. SOLUTION: This new polynucleotide is an isolated one and contains a nucleotide sequence at least 80% identical to a nucleotide sequence which codes a polypeptide having an amino acid sequence shown by the formula or the fragment corresponding thereto, or complementary to the above nucleotide sequence. It can be used to produce, e.g. 7TM receptor capable of binding to G-protein by coding the 7TM receptor, which is useful for, e.g. prevention or treatment of infectious diseases (e.g. those by bacteria, fungi or viruses such as HIV), cancers, asthma, high blood pressure, myocardinal infarction, allergy, dementia or the like. The polynucleotide is obtained by screening a human genome placenta library with a fragment corresponding to the partial clone as the probe.
BACKGROUND: The local anaesthetic lidocaine is widely used in the neonatal intensive unit to treat seizures in premature babies. However, other antiepileptics administered during early development in various animal models have shown negative long-term behavioural effects. Since no long-term behavioural data so far exist regarding lidocaine exposure at an early age, we decided to perform this extended follow-up study using a sensitive behavioural test.
METHODS: Neonatal mice received a subcutaneous administration of saline or one dose of lidocaine (0.5, 4, or 12 mg kg-1) on postnatal day 10 (P10; peak of the Brain Growth Spurt). A well-established test to detect long-term behavioural alterations was conducted at 2 and 6 months of age, corresponding to early and late adulthood in humans.
RESULTS: All animal survived to later testing. No signs of acute toxicity were observed. Lidocaine exposure did not result in any negative behavioural effects during habituation to a new home environment at any of the two studied time points, compared to saline placebo.
CONCLUSIONS: Lidocaine does not by itself produce any negative long-term behavioural effects in mice exposed in early life (P10) despite long-term follow-up. This is reassuring regarding the current practice of treating seizures in premature babies with intravenous lidocaine.
For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
PURPOSE: To obtain an oral preparation comprising an inner core containing an active compound, an enteric layer wrapping an erodible polymer layer, capable of releasing the drug at colon. CONSTITUTION: This delivery system is a tablet comprising 10-45 wt.%. of the tablet of the inner core containing a biologically active compound and a drug carrier, 30-85 wt.%. of the erodible polymer layer wrapping the inner core and 5-25 wt.%. of the enteric layer wrapping the erodible polymer layer and the core. The erodible polymer layer has 2.0-3.5 mm of thickness, consists of cellulose-ethers (e.g.; hydroxypropyl-methylcellulose) having 3-100 cPs of viscosity in 2%W/W concentration of aqueous solution, the erodible polymer contains cellulose-ethers in the weight ratio of 6:1-0.5:1 to fine crystalline cellulose. The enteric layer is coated in 50-300 μm of thickness. A drug delivery system capable of decreasing drug release at the organs excluding the target is realized.
This study aimed to explore the potential of liquid biopsy as a diagnostic tool by integrating two key biomarkers, Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA), and to enhance the detection fidelity of prostate cancer. A dual biomarker analysis approach was employed to synergize the sensitivities of CTCs and ctDNA. Various genetic mutations of ctDNA and tissues were scrutinized, investigating their prevalence, co-existence, and mutual exclusivity. The findings uncovered a more intricate mutation landscape than previously anticipated, indicating a complex interplay between cellular and genetic aberrations in prostate cancer. Through harnessing the combined power of CTCs and ctDNA, our dual biomarker approach provides a more comprehensive understanding of prostate cancer genetics. This has the potential to revolutionize early detection and guide personalized therapeutic interventions.
The invention discloses a cefuroxime sodium compound prepared through an advanced on-line process control technology and a preparation thereof. The project of high-grade medical product refining crystallization technology research and development and industrialization receives national scientific and technological progress second prize in 2015. The advanced on-line process control technology belongs to the high-grade medical product refining crystallization technology. An X ray powder diffraction test on cefuroxime sodium shows that in the spectrum, main characteristic peaks represented by diffraction angle 2theta are as follows: 9.71 degrees, 14.18 degrees, 16.19 degrees, 21.10 degrees, 22.88 degrees, 25.16 degrees and 30.77 degrees. The compound has the characteristics of high purity, low impurity content, good fluidity and good stability. The preparation is a cefuroxime sodium injection.
Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
The aims of this study were to determine the distribution and prevalence of gastroenteritis caused by human adenovirus (HAdV) in children in Yunnan province, China, in 2015-2021 and to identify preventive measures that can be taken to reduce morbidity and mortality in children.HAdV is a significant agent of diarrhea in children, but limited data are available regarding the epidemiology and genetic diversity of HAdV in children with diarrhea in Yunnan province, China. A total of 1754 fecal samples were subjected to real-time RT-PCR to detect and quantify HAdV. Positive samples were further analyzed using next-generation sequencing (NGS), and epidemiological data were analyzed as well.1754 patients with diarrhea were enrolled, of which 1041 were male and 713 were female (M:F ratio: 1.46). Seventy-two stool samples out of 1754 (4.10%) were positive for HAdV. The detection rates of all age groups varied from 2.50-4.78%. The highest incidence of HAdV was observed in children under 2 years of age, especially in children 12-24 months-old. From 2015-2021, the annual detection rate ranged from 1.62-12.26%. HAdV was detected throughout the year, but with marked seasonality. Children were most likely to be positive for HAdV in June and November. We detected HAdV in 15.53% (16/103) of samples collected in June and in 8.19% (14/171) of those collected in November. The entire viral genome was successfully sequenced for 13 of the 72 HAdV-positive samples, and 76.92% (10/13) of these were classified as genotype F41 and 23.08% (3/13) were classified as genotype C2.ConclusionsIn Yunnan province, children of all ages are susceptible to HAdV infection, but there has been marked variation in the yearly prevalence. The highest rate of HAdV detection was in June, followed by November. Priority should be given to disease prevention over the development of targeted antiviral therapies, and effective vaccines for preventing HAdV diarrhea are needed. It is also important to establish a surveillance system to collect relevant clinical and epidemiological data quickly in order to assess the potential risk of HAdV infection in children and to identify epidemic strains for the development of effective vaccines.
A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
Age, ethnic background and genetic components have been identified as the established risks for prostate cancer (PCa). Pentraxin 3 (PTX3), originally identified as a pattern-recognition molecule for defence against infectious agents, has multiple functions in tissue repair and in the regulation of cancer-associated inflammation. In this study, we sought to investigate the impact of PTX3 gene variants on the development of PCa. Genotypes of four common single-nucleotide polymorphisms (SNPs) of PTX3 gene, including rs1840680, rs2305619, rs3816527 and rs2120243, were profiled among 705 PCa patients and 705 ethnicity-matched controls. In this study, we found that patients who carry at least one minor allele (C) of rs3816527 (AC and CC) tended to develop advanced forms of diseases (clinical large T stage, OR, 1.593, p = 0.032; pathologically-confirmed nodal spread, OR, 1.987, p = 0.011; metastatic tumour, OR, 3.896, p = 0.032) as compared with those homologous for the major allele (AA). Further stratification analysis showed that such association of rs3816527 with lymphatic and distal metastasis of PCa was accentuated in the younger age group (≤65 at diagnosis) but not seen in the older age group (>65 at diagnosis), suggesting an age-specific effect of PTX3 variants. Prediction of PTX3 protein structure implied that polymorphism may alter the quaternary organization and oligomerization of PTX3 protein. Moreover, our gene silencing experiments and survey of public datasets revealed that elevation of PTX3 levels in PCa was required for cell migration and associated with tumour metastasis. Our results highlight an association of PTX3 rs3816527 with the progression of PCa.
Emphysema, myofibroblast accumulation and airway remodeling can occur in the lungs due to exposure to atmospheric pollution, especially fine particulate matter (PM2.5), leading to chronic obstructive pulmonary disease (COPD). Specifically, bronchial epithelium-fibroblast communication participates in airway remodeling, which results in COPD. An increasing number of studies are now being conducted on the role of exosome-mediated cell-cell communication in disease pathogenesis. Here, we investigated whether exosomes generated from bronchial epithelial cells could deliver information to normal stromal fibroblasts and provoke cellular responses, resulting in airway obstruction in COPD. We studied the mechanism of exosome-mediated intercellular communication between human bronchial epithelial (HBE) cells and primary lung fibroblasts (pLFs). We found that PM2.5-induced HBE-derived exosomes promoted myofibroblast differentiation in pLFs. Then, the exosomal lncRNA expression profiles derived from PM2.5-treated HBE cells and nontreated HBE cells were investigated using an Agilent Human LncRNA Array. Combining coculture assays and direct exosome treatment, we found that HBE cell-derived exosomal HOTAIRM1 facilitated the myofibroblast differentiation of pLFs. Surprisingly, we discovered that exosomal HOTAIRM1 enhanced pLF proliferation to secrete excessive collagen secretion, leading to airway obstruction by stimulating the TGF-β/SMAD3 signaling pathway. Significantly, PM2.5 reduced FEV1/FVC and FEV1 and increased the level of serum exosomal HOTAIRM1 in healthy people; moreover, serum exosomal HOTAIRM1 was associated with PM2.5-related reductions in FEV1/FVC and FVC. These findings show that PM2.5 triggers alterations in exosome components and clarify that one of the paracrine mediators of myofibroblast differentiation is bronchial epithelial cell-derived HOTAIRM1, which has the potential to be an effective prevention and therapeutic target for PM2.5-induced COPD.
PURPOSE:To specifically detect an antibody (HCV antibody) having specificness to non-A non-B type hepatitis-associated antigen with a high sensitivity and high degree by consisting the above measuring reagent of peptide having the amino acid array expressed by specific formula. CONSTITUTION:The peptide having the amino acid array expressed by the formula I is synthesized by a solid phase synthesis method to obtain the measuring reagent of the HCV antibody. A carrier is coated with this measuring reagent as an antigen material and thereafter, a block agent is acted to block the nonspecific protein conjugated section on the carrier. A sample to be inspected is added to the carrier coated with the measuring reagent and is incubated. An enzyme labeled antibody is then brought into contact therewith and the carrier is incubated. A substrate is added to the carrier treated in such a manner and the carrier is incubated. The decomposed quantity of the carrier is measured by using an absorptiometer. The HCV antibody to the non-A non-B type hepatitis-associated antigen after blood transfusion is detected specifically with the high sensitivity in this way.
In Parkinson's disease, imbalances between 'antikinetic' and 'prokinetic' patterns of neuronal oscillatory activity are related to motor dysfunction. Invasive brain recordings from the motor network have suggested that medical or surgical therapy can promote a prokinetic state by inducing narrowband gamma rhythms (65-90 Hz). Excessive narrowband gamma in the motor cortex promotes dyskinesia in rodent models, but the relationship between narrowband gamma and dyskinesia in humans has not been well established. To assess this relationship, we used a sensing-enabled deep brain stimulator system, attached to both motor cortex and basal ganglia (subthalamic or pallidal) leads, paired with wearable devices that continuously tracked motor signs in the contralateral upper limbs. We recorded 984 h of multisite field potentials in 30 hemispheres of 16 subjects with Parkinson's disease (2/16 female, mean age 57 ± 12 years) while at home on usual antiparkinsonian medications. Recordings were done 2-4 weeks after implantation, prior to starting therapeutic stimulation. Narrowband gamma was detected in the precentral gyrus, subthalamic nucleus or both structures on at least one side of 92% of subjects with a clinical history of dyskinesia. Narrowband gamma was not detected in the globus pallidus. Narrowband gamma spectral power in both structures co-fluctuated similarly with contralateral wearable dyskinesia scores (mean correlation coefficient of ρ = 0.48 with a range of 0.12-0.82 for cortex, ρ = 0.53 with a range of 0.5-0.77 for subthalamic nucleus). Stratification analysis showed the correlations were not driven by outlier values, and narrowband gamma could distinguish 'on' periods with dyskinesia from 'on' periods without dyskinesia. Time lag comparisons confirmed that gamma oscillations herald dyskinesia onset without a time lag in either structure when using 2-min epochs. A linear model incorporating the three oscillatory bands (beta, theta/alpha and narrowband gamma) increased the predictive power of dyskinesia for several subject hemispheres. We further identified spectrally distinct oscillations in the low gamma range (40-60 Hz) in three subjects, but the relationship of low gamma oscillations to dyskinesia was variable. Our findings support the hypothesis that excessive oscillatory activity at 65-90 Hz in the motor network tracks with dyskinesia similarly across both structures, without a detectable time lag. This rhythm may serve as a promising control signal for closed-loop deep brain stimulation using either cortical or subthalamic detection.